When was Zenas BioPharma founded?

Zenas BioPharma was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Zenas BioPharma located?

Zenas BioPharma is headquartered in Fort Myers, United States.

How many employees does Zenas BioPharma have?

As of Sep 30, 2026, the latest employee count at Zenas BioPharma is 209.

Is Zenas BioPharma a funded company?

Zenas BioPharma is a funded company, having raised a total of $318M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 2021.

When was the latest funding round of Zenas BioPharma?

Zenas BioPharma's latest funding was a $***** Series C round on May 03, 2024, with participation from 15 investors.

What is the annual revenue of Zenas BioPharma?

Annual revenue of Zenas BioPharma is between $10M and $50M as on Dec 31, 2025

Where does Zenas BioPharma rank among its competitors?

Zenas BioPharma ranks 1st amongst 29 active competitors, of which 2 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Cerium, which secured $750K in May, 2026.

Who are the top competitors of Zenas BioPharma?

Zenas BioPharma's top competitors include CTI Clinical Trial, AllStripes and Prime Global. Among them, Cerium secured the most recent funding round in May, 2026.

Zenas BioPharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Zenas BioPharma is a public company based in Fort Myers (United States), founded in 2020 by Lonnie Moulder. It operates as a Provider of clinical development services for autoimmune and rare diseases. Zenas BioPharma has raised $318M in funding from investors like New Enterprise Associates, SR One and Norwest. The company has 29 active competitors, including 2 funded and 4 that have exited. Its top competitors include companies like CTI Clinical Trial, AllStripes and Prime Global.

Company Details

Website: zenasbio.com
Email ID: *****@zenasbio.com

Key Metrics

Founded Year

2020

Location

Fort Myers, United States

Stage

Public

Total Funding

$318M in 3 rounds

Latest Funding Round

Series C, May 03, 2024, $*****

Investors

New Enterprise Associates & 20 more

Ranked

1^st among 29 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

209 as on Sep 30, 2026

Similar Companies

CTI Clinical Trial & 30 more

Exit Details

Public

View Zenas BioPharma's full profile

Zenas BioPharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Zenas Biopharma, Inc. CIN: 1953926 , United States, Active		$10M - $50M (As on Dec 31, 2025)	-	-

Zenas BioPharma got listed on Sep 13, 2024.

Click here to take a look at Zenas BioPharma's IPO in detail

Zenas BioPharma has raised a total funding of $318M over 3 rounds. Its first funding round was on Mar 2021. Its latest funding round was a Series C round on May 03, 2024 for $*****. 15 investors participated in its latest round. Zenas BioPharma has 21 institutional investors.

Here is the list of recent funding rounds of Zenas BioPharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 03, 2024	7901876	Series C	7561572	5489947	6357998	5747146
Nov 02, 2022	7820102	Series B	2953914	6296239	9983105	Longitude Capital & 11 more
Mar 2021	8011580	Series A	1521411	8571347	6055883	5768550

Access funding benchmarks and valuations. Sign up today!

View details of Zenas BioPharma's funding rounds and investors

The founders of Zenas BioPharma is Lonnie Moulder.

Here are the details of Zenas BioPharma's key team members:

Lonnie Moulder: Founder of Zenas BioPharma and founder of 1 other company.
Contact Info: 2 email addresses

View details of Zenas BioPharma's Founder profiles and Board Members

Zenas BioPharma's employee count trend

Zenas BioPharma has 209 employees as of Sep 26. Here is Zenas BioPharma's employee count trend over the years:

Employee count trend for Zenas BioPharma

Uncover Zenas BioPharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Zenas BioPharma include CTI Clinical Trial, AllStripes and Prime Global. Here is the list of Top 10 competitors of Zenas BioPharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Zenas BioPharma 2020, Fort Myers (United States), Public	Provider of clinical development services for autoimmune and rare diseases	$318M	ArrowMark Partners, Perceptive Advisors & 19 others	67/100
2nd	CTI Clinical Trial 1999, Cincinnati (United States), Unfunded	Clinical research organization providing comprehensive services for drug and device development	-	-	52/100
3rd	AllStripes 2017, San Francisco (United States), Acquired	Provider of information to patients and communities with the medical data for rare diseases	$67M	Lux Capital, Spark Capital & 16 others	51/100
4th	Prime Global 1997, London (United Kingdom), Late Stage	Provider of medical communication solutions	-	LLCP, HSBC & 1 others	47/100
5th	Cerium 2012, Gaithersburg (United States), Series A	CRO focusing on developing and commercialising of drugs for the treatment of orphan diseases	$11.9M	-	41/100
6th	Agility Clinical 2012, Carlsbad (United States), Acquired	CRO with a special focus on orphan drug development	$390K	-	40/100
7th	RDMD 2017, San Francisco (United States), Deadpooled	Provider of patient-centered clinical research platform and services for rare disease drug development	-	-	39/100
8th	Neurenati 2020, Montreal (Canada), Seed	Biotech company focused on developing therapies for rare diseases, with a current focus on Hirschsprung disease	$2.9M	Invest Quebec	38/100
9th	Oddifact France, Unfunded	Developer of AI-driven platform identifying and licensing orphan drug designations.	-	-	35/100
10th	Elpida Therapeutics 2023, Encino (United States), Unfunded	Biotechnology company focused on developing gene therapies for rare and ultra-rare diseases	-	-	35/100